Abstract
Prenatal therapy with prostanoids is considered as a potential non-invasive treatment strategy for congenital diaphragmatic hernia (CDH). Before assessing the efficacy of the drug in a rat disease model, transplacental transfer as well as fetal and maternal tolerance to the drug need to be demonstrated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
